Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - Results from the efficacy phase of the APH-19 study

• L. Masana,
• A. Zambon,
• C.P. Schmitt,
• C. Taylan,
• J. Driemeyer,
• H. Cohen,
• P.S. Buonuomo,
• A. Alashwal,
• M. Al-Dubayee,
• J.L. Diaz-Diaz,
• F. Maatouk,
• S. Martínez Hervás,
• B. Mangal,
• S. Löwe,
• T. Cunningham

Affiliations

L. Masana

Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV CIBERDEM, Reus, Spain

A. Zambon

Department of Medicine, University of Padua, Padua, Italy

C.P. Schmitt

Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

C. Taylan

Department of Pediatric Nephrology, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany

J. Driemeyer

Department of Pediatrics, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

H. Cohen

Strassburger Lipid Center, Sheba Medical Center, Tel Hashomer, Israel

P.S. Buonuomo

Rare Diseases and Medical Genetics Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

A. Alashwal

Dialysis & Apheresis Centres, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

M. Al-Dubayee

King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

J.L. Diaz-Diaz

Department of Internal Medicine, University Hospital of A Coruña, A Coruña, Spain

F. Maatouk

Cardiology Department, Monastir Hospital, Monastir, Tunisia

S. Martínez Hervás

Department of Endocrinology and Nutrition, Clinic University Hospital of Valencia, Valencia, Spain

B. Mangal

Solara Consulting Corp, North Vancouver, Canada

S. Löwe

Amryt Research Ltd, Dublin, Ireland

T. Cunningham

Amryt Research Ltd, Dublin, Ireland